Shares of Repligen Corp. (NASDAQ:RGEN) fell 3.5% on Thursday . The company traded as low as $26.76 and last traded at $26.76, with a volume of 78,924 shares trading hands. The stock had previously closed at $27.73.

A number of research firms have weighed in on RGEN. Jefferies Group restated a “hold” rating and issued a $28.00 price target on shares of Repligen Corp. in a research note on Monday, June 13th. Zacks Investment Research cut Repligen Corp. from a “hold” rating to a “sell” rating in a research note on Wednesday, June 8th.

The firm’s 50 day moving average price is $24.43 and its 200-day moving average price is $25.34. The firm has a market cap of $933.45 million and a P/E ratio of 115.62.

Repligen Corp. (NASDAQ:RGEN) last posted its quarterly earnings data on Thursday, May 5th. The company reported $0.12 EPS for the quarter, beating the Zacks’ consensus estimate of $0.10 by $0.02. The company had revenue of $25.10 million for the quarter, compared to analyst estimates of $22.54 million. During the same quarter in the prior year, the business earned $0.12 EPS. Repligen Corp.’s revenue was up 20.5% compared to the same quarter last year. On average, equities analysts predict that Repligen Corp. will post $0.47 EPS for the current year.

In related news, VP Howard Benjamin sold 2,889 shares of the firm’s stock in a transaction that occurred on Wednesday, May 11th. The shares were sold at an average price of $26.72, for a total transaction of $77,194.08. Following the completion of the sale, the vice president now directly owns 18,626 shares in the company, valued at $497,686.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Thomas F. Ryan, Jr. sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 30th. The stock was sold at an average price of $26.60, for a total transaction of $133,000.00. Following the sale, the director now owns 12,094 shares of the company’s stock, valued at $321,700.40. The disclosure for this sale can be found here.

Other hedge funds have modified their holdings of the company. Russell Frank Co boosted its stake in shares of Repligen Corp. by 12.7% in the fourth quarter. Russell Frank Co now owns 66,506 shares of the company’s stock worth $1,933,000 after buying an additional 7,498 shares during the last quarter. Nationwide Fund Advisors boosted its stake in shares of Repligen Corp. by 14.4% in the fourth quarter. Nationwide Fund Advisors now owns 82,025 shares of the company’s stock worth $2,320,000 after buying an additional 10,350 shares during the last quarter. California State Teachers Retirement System boosted its stake in shares of Repligen Corp. by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 60,884 shares of the company’s stock worth $1,722,000 after buying an additional 984 shares during the last quarter. Rhumbline Advisers boosted its stake in shares of Repligen Corp. by 9.4% in the fourth quarter. Rhumbline Advisers now owns 57,619 shares of the company’s stock worth $1,630,000 after buying an additional 4,970 shares during the last quarter. Finally, Columbus Circle Investors boosted its stake in shares of Repligen Corp. by 35.5% in the fourth quarter. Columbus Circle Investors now owns 572,732 shares of the company’s stock worth $16,203,000 after buying an additional 150,123 shares during the last quarter.

Repligen Corporation is a bioprocessing company. The Company is focused on the development, production and commercialization of products used in the process of manufacturing biologic drugs (bioprocessing). The Company is a manufacturer of both native and recombinant forms of Protein A, critical reagents used in biomanufacturing to separate and purify monoclonal antibodies, a type of biologic drug.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.